CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 419 enrolled
Drug / intervention
Geenius HIV1/2 Supplemental Assaydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02401555
NCT02401555N/ACompleted
CompareCT.gov

Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay

Bio-Rad Laboratories·observational·Posted Mar 30, 2015·Updated Mar 28, 2017

In Brief

An observational study evaluating Geenius HIV1/2 Supplemental Assay for HIV. Completed, enrolled 419 participants across 5 sites.

Detailed Summary

The purpose of this study was to evaluate the performance of the Bio-Rad Geenius HIV 1/2 Supplemental Assay, a single-use immunochromatographic assay for the confirmation and differentiation of individual antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV-1 and HIV-2) in fingerstick whole blood, venous whole blood, serum, or plasma samples (EDTA, heparin, and sodium citrate).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 30, 2015
Enrollment StartApr 1, 2013
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.3 years ago

Interventions

Geenius HIV1/2 Supplemental Assaydevice

The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).